Results 121 to 130 of about 1,009 (151)

Different Presentations and Different Treatment Options in Blastic Plasmacytoid Dendritic Cell Neoplasms: A Case Series. [PDF]

Int J Hematol Oncol Stem Cell Res
Cengiz E, Aydin MS, Gunes AK, Ceran F, Dagdas S, Ozet G.   +5 more
europepmc   +1 more source

Localized blastic plasmacytoid dendritic cell neoplasm associated with progressive clonal hematopoiesis and myelodysplastic syndrome. [PDF]

APMIS
Julin C, Nielsen SL, Grantzau TL, Ahmad SA, Cowland JB, Bonde J, Nørgaard P.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Targeting CD123 in BPDCN: an emerging field

Expert Review of Hematology, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on targeted therapy to improve responses and limit potential toxicity.CD123 (also known as IL-3 Rα) is a cell surface marker and ...
Adam J DiPippo, Nathaniel R Wilson, Naveen Pemmaraju   +2 more
openaire   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — diagnostic and therapeutic challenge

Hematology in Clinical Practice, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy. The disease usually affects the skin, bone marrow, peripheral blood and less commonly lymph nodes. The actual incidence of BPDCN is currently unknown.
Jarosław Wajs, Małgorzata Lewandowska, Przemysław Kluge, Lucyna Drążek, Dorota Jesionek-Kupnicka   +4 more
openaire   +1 more source

Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Pharmacotherapy, 2022
Unique among hematologic malignancies, blastic plasmacytoid dendritic cell neoplasm (BPDCN) affects multiple compartments including bone marrow, hematologic, lymphatic, dermatologic, and central nervous systems (CNS). Treating BPDCN is challenging, historically, as patients display refractoriness to chemotherapy and absence of long-term remissions in ...
Nathaniel R. Wilson, Naveen Pemmaraju
openaire   +2 more sources

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a clonal disease derived from precursors of plasmacytoid dendritic cells (pDC). It is a rare neoplasm involving the skin which may or may not be associated from the outset with a leukemic component.
Poret, Eve, Delettre, Fanny Angelot, Biichle, Sabeha, Roogy, Anne, Benazet, Louis, Pagadoy, Maider, Vidal, Chrystelle, Leroux, Franck, Harriverl, Veronique, Ferrand, Christophe, Salaun, Veronique, Benseddik, Zehaira, Guy, Julien, Jacob, Marie Christine, Roumier, Christophe, Feuillard, Jean, Vila, Liliana, Baseggio, Lucile, Plesa, Adriana, Arnoulet, Christine, Benet, B., Drénou, Bernard, Cannard, Veronique Latger, Béné, Marie-Christine, Ticchioni, Michel, Lusina, Daniel, Bardet, Valerie, Tavernier, Magalie L. E. Garff, Macintyre, Elizabeth, Asnafi, Vahid, Noguera, Maria Elena, Bouyer, Sabrina, Lafon, Carine Lecoq, Roussel, Mikael, Jardin, Fabrice, Solly, Françoise, Campos, Lydia, Galoisy, Anne, Arnaud, Anne, Daliphard, Sylvie, Geneviève, Franck, Lacroix, Romaric, Schillinger, Françoise, Seilles, Estelle, Binda, Delphine, Deconinck, Eric, Saas, Philippe, Ottou, Francine Garnache   +47 more
openaire   +2 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Current Hematologic Malignancy Reports, 2018
Engagement on social media for professional, healthcare-related communication is rapidly rising around the world. We aimed to better understand the dynamics of a rare disease Twitter hashtag community.Twitter has served as a platform for academic discussion, a method for knowledge dissemination directly from medical meetings, and a venue for patient ...
Pemmaraju, Naveen, Utengen, Audun, Gupta, Vikas, Thompson, Michael A, Lane, Andrew A   +4 more
openaire   +3 more sources

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

Current Hematologic Malignancy Reports, 2017
The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for ...
Naveen, Pemmaraju, Audun, Utengen, Vikas, Gupta, Michael A, Thompson, Andrew A, Lane   +4 more
openaire   +2 more sources

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2019
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONRIS, Stemline Therapeutics) for the treatment of adult and pediatric BPDCN has ...
Mansour Alfayez, Marina Konopleva, Naveen Pemmaraju   +2 more
openaire   +2 more sources